AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Mar 20, 2023

New approach uses microbiome to treat skin disease

Rather than reducing skin inflammation, repair the injured skin microbiome that allowed inflammation to flare in the first place.


Richard L. Gallo, MD, PhD, FAAD
Richard L. Gallo, MD, PhD, FAAD

Dermatologists have been looking for new ways to treat atopic dermatitis (AD) for decades. Rather than reducing skin inflammation alone, is it possible to repair the injured skin microbiome that allowed inflammation to flare in the first place?

“What is needed for a cure is not just immune suppression, but the reestablishment of a healthy skin microbiome,” said Richard L. Gallo, MD, PhD, FAAD, distinguished professor, Irma Gigli chair, and founding chair of Dermatology at the University of California San Diego. Dr. Gallo explored a new model for AD during his Eugene J. Van Scott Award for Innovative Therapy of the Skin and Phillip Frost Leadership Lecture Human Skin Commensal Microbes for Bacteriotherapy of Atopic Dermatitis during the “P151 – Plenary” on Sunday. “There is an atopic holobiont — the community of host and the many other species living in or around it — that can be modified using bacteriotherapy (the application of therapeutic bugs) to reestablish a healthy holobiont and more effectively treat disease.” 

New findings suggest AD develops and flares when the skin microbiome is perturbed due to environment, allergens, stress, antibiotics, and other factors. Overgrowth of pathogenic species drive cycles of inflammation that manifest as AD. 

Genomes and microbiomes

“Increased antibiotic use starting in the 1970s and 1980s resulted in a welcome decrease in the incidence of infectious disease but also the alarming rise in autoimmune disease,” Dr. Gallo said. “The Human Genome Project, the NIH Human Microbiome Project, and other efforts found that while the human genome has around 23,000 genes, the human microbiome has more than 1 million genes. Health and disease result from a complex interplay between host and microbiome that we are just beginning to understand and explore.” 

The gut microbiome has garnered significant attention, he said, but the skin is the largest human interface with the environment and microbiota. More than 100 species of bacteria are protected within follicles alone. Skin health is the interplay between the epidermis, bacteria living on and within the skin — that act on each other as well as on the host and host immune system — and the immune system, which affects both epidermis and microbes. 

The role of peptides

The skin produces its own antimicrobial peptides (AMPs) to help control pathogenic species. Beneficial species also control their pathogenic competitors. AD features an overgrowth of both S. aureus and S. epidermis. Patients with AD have deficient AMP production, allowing pathogenic growth. S. aureus and S. epidermis toxins cause barrier disruption and allergic sensitization. 

The same bacteria promote Th2 inflammation, at least in part by amplifying IL-4, a proinflammatory cytokine. Patients treated with an IL-4 receptor inhibitor such as dupilumab show a reduction in S. aureus and inflammation. 

Reestablishing healthy skin

Antibiotic therapy only exacerbates an already imbalanced skin microbiome, Dr. Gallo noted. Bacteriotherapy can move the skin microbiome toward healthy homeostasis. Phase 1 trials of S. hominis A9 isolated from healthy skin demonstrated safety and showed indications of therapeutic effect. 

“You’re not blowing away the skin microbiome with bacteriotherapy. You are reestablishing the balance of a healthy epidermis,” Dr. Gallo said. “Antimicrobials from the host and a normal skin microbiome control disease in atopic dermatitis. We don’t have a therapy yet, but work is moving in the right direction.”

Visit AAD DermWorld Meeting News Central for more articles.

Interesting Stories
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
More in AAD 2023 Annual Meeting
Safi Bahcall
AAD 2023 Annual Meeting
Nurture the unexpected
Mar 20, 2023
Camp Discovery 92
AAD 2023 Annual Meeting
Refer a patient to Camp Discovery!
Mar 20, 2023
Amy J. McMichael, MD, FAAD
AAD 2023 Annual Meeting
A question of belonging
Mar 20, 2023
David J. Margolis, MD, PhD, FAAD
AAD 2023 Annual Meeting
Dermatologists top the list in antibiotic prescriptions
Mar 20, 2023
22 698 Ia23 Web Card 3x2
AAD 2023 Annual Meeting
Mark your calendar for Innovation Academy 2023
Join the learning
Mar 20, 2023
Getty Images 479036574
AAD 2023 Annual Meeting
Save the date for the 2024 Annual Meeting
Mark you calendar for AM2024
Mar 20, 2023
2022 03 21 12 20 34 6238b40dd1e28
AAD 2023 Annual Meeting
Access your Certificate of Attendance
Download online
Mar 20, 2023
2022 03 21 12 26 25 6238b55bf2d38
AAD 2023 Annual Meeting
Claim CME
Claim CME
Mar 20, 2023
Aad March20
AAD 2023 Annual Meeting
Session highlights for Monday
Mar 20, 2023
Jane Margaret Grant-Kels, MD, FAAD
AAD 2023 Annual Meeting
Ethical dilemmas hiding in plain sight
Mar 20, 2023
John T. Schiller, PhD
AAD 2023 Annual Meeting
Taking on cervical cancer, one shot at a time
Mar 20, 2023
Cause Marketing
AAD 2023 Annual Meeting
Support your patients, win prizes!
Mar 19, 2023
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.